Free Trial

Oruka Therapeutics (ORKA) Competitors

Oruka Therapeutics logo
$15.26 -0.08 (-0.49%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ORKA vs. MESO, DNLI, ADPT, ANIP, CGON, VCEL, SRPT, BEAM, ARQT, and TWST

Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Mesoblast (MESO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), Vericel (VCEL), Sarepta Therapeutics (SRPT), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

Oruka Therapeutics vs. Its Competitors

Mesoblast (NASDAQ:MESO) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mesoblast presently has a consensus target price of $18.00, suggesting a potential upside of 13.10%. Oruka Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 164.67%. Given Oruka Therapeutics' higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Mesoblast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.20
Oruka Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Oruka Therapeutics has lower revenue, but higher earnings than Mesoblast.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$5.90M345.27-$87.96MN/AN/A
Oruka TherapeuticsN/AN/A-$83.72M-$2.81-5.43

Mesoblast's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
Oruka Therapeutics N/A -26.26%-24.16%

In the previous week, Oruka Therapeutics had 4 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Oruka Therapeutics and 7 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.99 beat Oruka Therapeutics' score of 0.56 indicating that Mesoblast is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
1 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mesoblast has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500.

Summary

Oruka Therapeutics beats Mesoblast on 6 of the 11 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORKA vs. The Competition

MetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$571.30M$2.46B$5.59B$9.82B
Dividend YieldN/A1.68%4.60%4.11%
P/E Ratio-5.4321.9930.2125.67
Price / SalesN/A683.80448.53106.03
Price / CashN/A183.0237.7558.93
Price / Book1.684.718.436.01
Net Income-$83.72M$31.61M$3.26B$264.94M
7 Day Performance11.59%3.65%3.90%2.65%
1 Month Performance3.78%3.03%4.16%1.49%
1 Year PerformanceN/A13.41%35.99%29.16%

Oruka Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORKA
Oruka Therapeutics
2.9341 of 5 stars
$15.26
-0.5%
$40.38
+164.7%
N/A$571.30MN/A-5.43N/ANews Coverage
Earnings Report
Analyst Forecast
Analyst Revision
MESO
Mesoblast
1.5489 of 5 stars
$15.00
+2.0%
$18.00
+20.0%
+140.7%$1.92B$5.90M0.0080Gap Up
DNLI
Denali Therapeutics
4.2729 of 5 stars
$13.03
-6.4%
$33.85
+159.8%
-35.7%$1.90B$330.53M-4.91430News Coverage
Earnings Report
Analyst Revision
Gap Down
ADPT
Adaptive Biotechnologies
2.6139 of 5 stars
$12.38
+1.9%
$12.38
0.0%
+185.1%$1.88B$178.96M-15.08790Gap Down
ANIP
ANI Pharmaceuticals
3.2548 of 5 stars
$86.55
+2.0%
$84.75
-2.1%
+50.5%$1.88B$614.38M-112.87600Earnings Report
Analyst Forecast
CGON
CG Oncology
1.4265 of 5 stars
$24.46
+2.2%
$55.30
+126.1%
-20.9%$1.87B$1.14M-13.8361Earnings Report
Analyst Revision
VCEL
Vericel
2.3694 of 5 stars
$36.59
+3.3%
$60.33
+64.9%
-17.5%$1.85B$237.22M305.78300Positive News
SRPT
Sarepta Therapeutics
4.6076 of 5 stars
$17.97
+0.2%
$44.17
+145.7%
-84.7%$1.76B$1.90B-20.691,372Trending News
Short Interest ↑
Gap Up
BEAM
Beam Therapeutics
2.2605 of 5 stars
$16.99
-1.0%
$48.45
+185.1%
-28.0%$1.73B$63.52M-3.79510Gap Up
ARQT
Arcutis Biotherapeutics
2.4746 of 5 stars
$14.23
+0.3%
$19.80
+39.1%
+57.1%$1.70B$196.54M-18.96150Analyst Revision
Gap Down
TWST
Twist Bioscience
3.9383 of 5 stars
$27.74
+0.4%
$49.40
+78.1%
-35.7%$1.67B$312.97M-19.10990

Related Companies and Tools


This page (NASDAQ:ORKA) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners